EXHIBIT 10.4
EXECUTION VERSION
AMENDMENT TO AMENDED AND RESTATED BINDING TERM SHEET
This AMENDMENT TO AMENDED AND RESTATED BINDING TERM SHEET (this
"AMENDMENT") is made effective as of December 27, 2004 by and between NORTHWEST
BIOTHERAPEUTICS, INC., a Delaware corporation (the "COMPANY"), and TOUCAN
CAPITAL FUND II, L.P., a Delaware limited partnership ("TOUCAN").
RECITALS
WHEREAS, the Company and Toucan are party to that certain Binding
Convertible Preferred Stock Term Sheet originally dated April 26, 2004 and
amended and restated on October 22, 2004 (as so amended and restated, the
"CONVERTIBLE PREFERRED STOCK TERM SHEET").
WHEREAS, concurrently herewith, the Company and its affiliates, if any,
and Toucan and its designees, are entering into Amendment No. 3 (the "THIRD
AMENDMENT") to that certain Amended and Restated Recapitalization Agreement by
and between the parties thereto; and
WHEREAS, in connection with the Third Amendment, the Company and Toucan
desire to amend the Convertible Preferred Stock Term Sheet as provided herein.
AGREEMENT
NOW, THEREFORE, for and in consideration of good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Company and Toucan agree as follows:
1. The paragraph of the Convertible Preferred Stock Term Sheet entitled
"Warrants:" is hereby amended and restated in its entirety as follows:
"The Company shall issue $6.75 million in warrant coverage on the first
$6.75 million Convertible Preferred Stock purchased for cash (the
"Preferred Stock Warrants"). Preferred Stock Warrants shall not be issued
upon conversion of notes, exercise of warrants, or other conversion or
exercise. The number of warrants to be so issued shall be determined on
the basis of $0.10 per share. If the total of $6.75 million is invested in
Convertible Preferred Stock, the number of warrants issued shall be
exercisable for 67.5 million shares of Convertible Preferred Stock. The
exercise price of such Preferred Stock Warrants shall be the lesser of
$0.10 per share (subject to adjustment for stock splits, stock dividends
and the like) and 35% discount to the average closing price during the
twenty trading days prior to the First Closing; provided, however, that in
no event will the exercise price be less than $.04 per share (subject to
adjustment for stock splits, stock dividends and the like). The exercise
period shall commence upon issuance of the Preferred Stock Warrants, and
shall continue for a period of seven (7) years after their respective
issuance dates."
2. The thirteenth bullet in the paragraph entitled "Conditions to Closing"
of the Convertible Preferred Stock term Sheet is hereby deleted in its entirety
and shall not be a
EXECUTION VERSION
condition precedent to the obligation of any Investor to Purchase Convertible
Preferred Stock from the Company.
3. Unless specifically modified or changed by the terms of this Amendment,
all terms and conditions of the Convertible Preferred Stock Term Sheet shall
remain in effect and shall apply fully as described and set forth in the
Convertible Preferred Stock Term Sheet.
4. This Amendment may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]
2.
EXECUTION VERSION
The Company and Toucan have executed this AMENDMENT TO AMENDED AND
RESTATED BINDING TERM SHEET as of the day and year first written above.
TOUCAN CAPITAL FUND II, L.P. NORTHWEST BIOTHERAPEUTICS, INC.
By: /s/ Xxxxx Xxxxxx By: /s/ Xxxxx Xxxxxxx
____________________________ _____________________________
Name: Xxxxx Xxxxxx Name: Xxxxx X. Xxxxxxx
Title: Managing Director Title: President
3.
